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Abstract
Background: The 4 dengue serotypes (DENV) are mosquito-borne pathogens that are associated with severe
hemorrhagic disease. DENV particles have a lipid bilayer envelope that anchors two membrane glycoproteins prM
and E. Two E-protein monomers form head-to-tail homodimers and three E-dimers align to form “rafts” that cover
the viral surface. Some human antibodies that strongly neutralize DENV bind to quaternary structure epitopes
displayed on E protein dimers or higher order structures forming the infectious virus. Expression of prM and E in
cell culture leads to the formation of DENV virus-like particles (VLPs) which are smaller than wildtype virus particles
and replication defective due to the absence of a viral genome. There is no data available that describes the
antigenic landscape on the surface of flavivirus VLPs in comparison to the better studied infectious virion.
Methods: A large panel of well characterized antibodies that recognize epitope of ranging complexity were used
in biochemical analytics to obtain a comparative antigenic surface view of VLPs in respect to virus particles. DENV
patient serum depletions were performed the show the potential of VLPs in serological diagnostics.
Results: VLPs were confirmed to be heterogeneous in size morphology and maturation state. Yet, we show that
many highly conformational and quaternary structure-dependent antibody epitopes found on virus particles are
efficiently displayed on DENV1–4 VLP surfaces as well. Additionally, DENV VLPs can efficiently be used as antigens to
deplete DENV patient sera from serotype specific antibody populations.
Conclusions: This study aids in further understanding epitopic landscape of DENV VLPs and presents a comparative
antigenic surface view of VLPs in respect to virus particles. We propose the use VLPs as a safe and practical
alternative to infectious virus as a vaccine and diagnostic antigen.
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Background
Dengue viruses (DENV) are mosquito-borne flaviviruses
responsible for dengue fever and dengue hemorrhagic
fever [1, 2]. DENVs are endemic in over 125 countries
and its global distribution is expected to expand due to
urbanization and other environmental factors that favor
the mosquito vector [3]. The DENV complex consists of
4 antigenically distinctive serotypes (DENV1–4). Infec-
tious DENV particles contain a positive stranded RNA
genome and capsid proteins surrounded by a lipid enve-
lope, which has two membrane glycoproteins designated
as pre-membrane (prM) and envelope (E). The outer
surface of the mature, infectious virus has a smooth sur-
face covered by E protein homodimers [4]. On the viral
surface, units of three E protein homodimers assemble
into raft-like structures and 30 rafts are packed tightly to
create a protein coat with icosahedral symmetry. The E
protein mediates viral attachment and entry into cells.
Additionally, the E protein is the major target of neutral-
izing and protective human antibodies. Recent studies
have demonstrated that most human antibodies that
strongly neutralize DENVs bind to quaternary structure
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E protein epitopes containing regions from 2 or more
proteins packed on the viral surface [5–8]. In other
words, many human antibodies target E protein epitopes
displayed on the viral surface but not on individual E
protein subunits. Soluble E protein subunit antigens are,
therefore, considered to be poor vaccine immunogens
because they lack higher order protein structures and
epitopes displayed on the intact virus. When flavivirus
prM and E proteins are co-expressed in cells, these pro-
teins assemble into virus-like particles (VLPs) that are
secreted from cells. Flavivirus VLPs have been produced
in a wide variety of expression platforms such as plants,
insect cells, bacteria, yeast and mammalian cells. Flavivi-
rus VLPs, which do not contain a viral nucleocapsid or
genomic RNA, are smaller than intact virions [9–12].
VLPs, often, share structural similarities and physico-
chemical features of the native virus, but are superior in
terms of safety, and ease of production and purification
[10]. VLPs have proven to be effective vaccine antigens
in preclinical or early stage clinical studies with different
enveloped viral pathogens such as West Nile virus, Tick-
borne encephalitis virus, Japanese encephalitis virus,
Zika virus, Chikungunya virus, Influenza virus and Den-
gue virus [10–17]. For DENV VLPs, no data is available
on the display and presentation of epitopes of varying
complexity recognized by human neutralizing antibodies.
Some structural information is available for tick-borne
encephalitis virus (TBEV) VLPs [12]. The low-resolution
cryo-EM image based reconstruction of TBEV VLPs in-
dicates that the number and organization of E proteins
on the VLPs are different from the infectious virus. Even
though TBEV VLPs are heterogeneous in size, investiga-
tors analyzed a uniform population of particles that were
smaller than virions and concluded that VLPs contain
30 E-homodimers assembled in a T = 1 icosahedral lat-
tice [12]. It is unclear if quaternary structure antibody
epitopes, especially those containing residues from dif-
ferent adjacent E homo-dimers, are displayed similarly
on VLPs and the larger infectious virions [12].
In this study we describe in detail the properties of epi-
topes present on DENV VLPs of all 4 serotypes using a large
panel of well-defined human mAbs and immune sera from
dengue patients. We directly compare the antigenic features
of DENV VLPs to whole virions and explore their use as
tools in serologic assays. Our results show the equivalence
between viruses and VLPs in a setting that is particularly
relevant for flavivirus vaccine development, diagnostics and
understanding the difference between virus and VLPs.
Methods
Production of DENV VLPs
Cells and viruses
Vero-81 cells were maintained at 37 °C as a monolayer
in Dulbecco’s modified Eagle’s medium (DMEM, Gibco)
supplemented with 5% fetal bovine serum (FBS), 1%
non-essential amino acids, 100 U/ml penicillin and
100 μg/ml streptomycin. Culture supernatants of
DENV1 WestPac-74, DENV2 S-16803, DENV3
CH53489 and DENV4 TVP-376 virus strains were used
to determine antibody binding and neutralizing activity
of depleted and undepleted serum. Purified DENV virus
preparations were obtained according to previously de-
scribed protocols [18] .
DENV virus-like particle production
The DENV virus-like particles (VLPs) were produced
and kindly provided by The Native Antigen Company,
Kidlington, UK. In short: recombinant dengue virus-like
particles consisting of DENV prM and E proteins were
transiently expressed in suspension culture adapted
HEK293 cells. Three days post transfection culture
supernatant was cleared by centrifugation and concen-
trated by tangential flow filtration. In a first step VLPs
were purified by a 2-step discontinuous sucrose gradient
with 20% and 40% sucrose densities. After a 6 h spin at
25,000 rpm in a SW28 rotor at 10 °C the 20%–40%
interphase was harvested by needle-stick. As a second
purification step ion exchange chromatography (Q Seph-
arose High Performance; GE Healthcare) was used in
negative mode once. VLPs were further purified by size
exclusion chromatography (Toyopearl HW-65F) which
also provided exchange of buffers to storage buffer. Puri-
fied DENV1–3 VLPs were stored in 10 mM sodium
phosphate, 20 mM sodium citrate, 154 mM sodium
chloride, pH 7.4. DENV4 VLPs were stored in Dulbec-
co’s phosphate buffered saline (DPBS) pH 7.4 containing
30% sucrose. VLP samples were stored at − 80 °C.
Virus and VLP analysis by western blot
Purified VLP samples were subjected to sodium dodecyl
sulphate polyacrylamide electrophoresis (SDS-PAGE)
and analyzed by western blot (WB) and Coomassie Bril-
liant Blue (CBB) staining. 500 ng of DENV VLP or puri-
fied DENV virus [18] were loaded into a gel loading
buffer (Biorad) supplemented with SDS. Samples were
boiled for 10 mins at 95 °C and subsequently spun down
at full speed for 2 mins. Following electrophoresis, sepa-
rated protein fractions were transferred to a nitrocellu-
lose membrane and blocked in blocking buffer (3% skim
milk in phosphate buffered saline (PBS) + 0.05%
Tween-20). Blocked membranes were incubated with
0.5 μg/ml 1 M7 mAb or 2G3 mAb in blocking buffer
for 1 h at 37 °C. Next, membranes were washed and
treated with (1:1000 in blocking buffer) AP-
conjugated anti-human IgG for 1 h at 37 °C. After
washing, membranes were developed by NBT/BCIP
AP substrate (Thermo Scientific).
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Epitope analysis by enzyme-linked immunosorbent assay
100 ng/well of 1M7 or 4G2 mAb was coated onto High-
binding Microlon plates (Greiner) in 0.1 M bicarbonate
buffer pH 9.6 overnight at 4 °C. Plates were washed 3
times with PBS + 0.1% Tween-20 and blocked with PBS
+ 3% skim milk + 0.05% Tween-20 for 1 h at 37 °C. Next,
plates were washed and incubated with serially diluted
purified virus or VLPs (of 2 separate preparations) in
blocking buffer for 1 h at 37 °C. After washing, the 1 M7
coated plates were incubated with the indicated serially
diluted mouse derived mAbs and the 4G2 coated plates
were incubated with indicated serially diluted human
mAbs (Table 1) for 1 h at 37 °C. After washing, mouse
mAb treated wells were incubated with 1:1000 anti-
mouse IgG-AP conjugated (Sigma) and human mAb
treated wells were incubated with 1:2500 anti-human
IgG-AP conjugated (Sigma). Plates were subsequently
washed and developed using AP-substrate (Sigma). Ab-
sorbance was measured at 405 nm.
The relative epitope display of each mAb tested was
determined for both the purified virus as the VLPs of
each serotype. The binding of all mAbs was normalized
against the binding of 1F4 for DENV1, 2D22 for
DENV2, 5 J7 for DENV3 and 5H2 for DENV4 to deter-
mine the relative epitope display of all other mAbs. The
normalized increase or decrease in mAb binding was
compared between virus and VLPs to give an indication
of which epitopes are displayed better on the virus and
VLP.
DT000 serum depletion
DT000 sera was derived from an individual > 10 years
post a secondary DENV infection (Table 1) and was di-
luted 1:10 in PBS and subjected the serum depletion
using DENV purified virus antigen or DENV VLPs (The
Native Antigen Company). 100 μg of 1 M7 mAb was
conjugated to 10 mg of Tosylactivated M280 magnetic
Dynabeads (Invitrogen) using manufacturers protocol.
1 M7 coated beads were blocked with 1% bovine serum
albumin (BSA) in PBS for 1 h at 37 °C. The beads were
washed 3 times with blocking buffer and incubated on a
rotator with 100 μg in 500 μl blocking buffer of purified
DENV antigen, DENV VLPs or BSA for 1 h at 37 °C.
Next, the beads were washed 3 times with PBS and
cross-linked with 4% PFA in 250 μl PBS for 30 mins at
room temperature. Next, the beads were washed 4 times
in PBS, resuspended in 100 μl PBS and subsequently di-
vided over two tubes for two rounds of depletion. 500 μl
of diluted serum was incubated with the beads for 1 h at
37 °C on a rotator. Next, the serum was transferred to
the second tube of beads for the second round of deple-
tion. Finally, the depleted serum was stored at 4 °C for
Table 1 Monoclonal antibody characterization
mAb/ polyclonal sera M/H/C Binding Neutralization (W/M/S) Binding region Binding DENV serotypes Ref
DV1 DV2 DV3 DV4 ZIKV
4G2 M F-CR W DII FL ++ ++ +++ +++ +++ [26]
1F4 H DV1 DV1:S DI/DII hinge Q +++ – – – – [7]
12C1.5 M D-CR DV:S DIII ++ ++ +++ ++ – [27]
1C19 H D-CR DV:M DII FL/BC ++ ++ ++ + ++ [28]
2D22 H DV2 DV2:S ZIKV:W DII/DIII Q – ++ – – – [5, 29]
5J7 H DV3 DV3:S DI/DII Q – – +++ – – [23]
5H2 C DV4 DV4:S DI Q – – – + – [24]
1 M7 H F-CR M DII FL +++ ++ +++ +++ +++ [30]
A11 (EDE2) H F-CR DV:S ZIKV:W DI/DII/DIII Q +++ +++ +++ +++ + [31]
B7 (EDE2) H F-CR DV:S ZIKV:W DI/DII/DIII Q +++ +++ +++ +++ + [31]
C8 (EDE1) H F-CR DV:S ZIKV:S DII/DIII Q +++ +++ +++ +++ ++ [31]
C10 (EDE1) H F-CR DV:S ZIKV:S DII/DIII Q +++ +++ +++ +++ ++ [31]
3H5 M DV2 DV2:S DIII LR – +++ – – – [32]
8A1 M DV3 DV3:S DIII – – +++ – – [33]
DV4 126 H DV4 DV4:S DI/DII hinge Q – – – +++ – [8]
DV4 131 H DV4 DV4:S DI/DII hinge Q – – – +++ – [8]
DV4 141 H DV4 None DIII – – – +++ – [8]
DT000 H D-CR DV:S ZIKV:W +++ +++ +++ ++ – [21]
Dengue specific monoclonal antibodies. A panel of well-defined mouse, human or chimpanzee (M/H/C) derived Mabs were used to characterize sRecE epitopes.
Flavivirus cross reactive (F-CR), dengue cross reactive (D-CR), weakly, moderately or strong (W/M/S) neutralizing, E-domain I, II, III (DI, DII, DIII), fusion loop (FL),
BC-loop (BC), lateral ridge (LR), quaternary (Q)
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further analysis by ELISA and flow based vero cell
neutralization assay.
DENV specific IgG ELISA
Microlon ELISA plates (Greiner) were coated with
100 ng/well of 4G2 mAb in 0.1 M bicarbonate buffer
pH 9.6 overnight at 4 °C. The plates were blocked with
PBS + 3% skim milk + 0.05% Tween-20 for 1 h at 37 °C.
Next, the plates were washed 3 times with PBS + 1%
Tween-20 and incubated with 1:10 diluted virus culture
supernatant in blocking buffer for 1 h at 37 °C. After
washing, the plates were incubated with depleted or
undepleted DT000 or DT168 serum (final concentration
1:50 diluted in blocking buffer) for 1 h at 37 °C. Next,
the plates were washed and incubated with 1:2500 anti-
human IgG-AP conjugated (Sigma) for 45 mins at 37 °C.
The plates were washed and developed with AP-
substrate (Sigma) and the absorbance was measured at
405 nm.
Vero cell neutralization assay
The neutralizing capacity of depleted and undepleted
DT000 serum was determined by flow based
neutralization assay as previously described [19, 20]. In
short: 25000 Vero cells/well were seeded in a 96-wells
flat-bottom culture plate and incubated overnight at 37 °
C. Depleted and undepleted sera were serially diluted in
OptiMem (Gibco) and incubated for 45 mins at 37 °C
with the appropriate amount of virus (resulting in 15%
of infected cells - amount previously determined). Cells
were washed with OptiMem and overlayed with the
virus/serum mix for 2 h at 37 °C. Next, cells were
washed and overlaid with Vero cell growth medium and
incubated overnight at 37 °C. The next day, cells were
detached using trypsin (Gibco) and transferred to a 96-
wells round bottom well plate. Cells were fixed in 4%
paraformaldehyde in PBS for 10 mins at room
temperature. Cells were subsequently washed in
permeabilization buffer and blocked with 1% normal
mouse serum in PBS for 30 mins at room temperature.
The cells were treated with Alexa fluor 488 conjugated
anti-prM Mab 2H2 and diluted 1:400 in blocking buffer
for 1 h at 37 °C. Cells were washed in permeabillization
buffer and finally resuspended in PBS + 1% FBS. The
percentage of infected cells was determined by flow cy-
tometry using a Guava® Flow Cytometer (EMD Milli-
pore) and the neutralizing efficiency of the sera was
expressed as neut50 values (the dilution where 50% of
the virus was neutralized) calculated using GraphPad
Prism software.
Transmission electron microscopy
Discharged copper 400 mesh formvar carbon coated
grids (Ted Pella Inc., Redding, CA, USA) were loaded
with 15 μl of purified DENV VLPs for 5 mins at room
temperature. The grids were washed in MilliQ water and
stained for 30 s with 2% uranyl acetate. Excess uranyl
acetate was removed by filter paper. The grids were fi-
nally air-dried at RT and observed with a LEO 910 trans-
mission electron microscope (Zeiss).
Results
Expression and purification of DENV VLPs
DENV1–4 prM-E sequences were expressed in mamma-
lian HEK 293 suspension cultures and purified by su-
crose gradient and ion-exchange chromatography.
Purified VLP fractions were subjected to SDS-PAGE and
analyzed by Coomassie stain (CBB; Fig.1a) and Western
Blot (WB) using a cross-reactive (CR) human derived
anti-E mAb 1 M7 and anti-prM 2G3 (Fig. 1b). All virus
and VLP samples showed a protein band of ~ 55 kDa,
corresponding to the estimated molecular weight of the
DENV E protein. There were some slight differences ob-
served in molecular weight between the 4 serotypes,
possibly due to differences in the number of N-linked
glycans. However, the size differences were consistent
a b
Fig. 1 Expression and characterization of DENV1–4 VLPs. Purified virus and VLPs were subjected to SDS-PAGE and analyzed with (a) CBB and (b)
WB using anti-E 1 M7 and anti prM 2G3 mAbs. E-dimers (ED), E-monomers (EM), prM and capsid (c) proteins are indicated. The prM/E ratio is
indicated below panel B and is determined using ImageJ software
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for the virus samples and the VLP samples. The levels of
prM seemed to differ between purified virus and VLP
samples. DENV1 and DENV2 VLPs appear to contain
more prM than their virus counterpart, while DENV4
VLPs had lower prM levels compared to DENV4 puri-
fied virus as determined by the prM/E ratio. However,
the difference in prM content and maturation differ-
ences between VLP serotypes need to be further ana-
lyzed in other more focused studies. E-dimer fractions
appeared more prominent in the virus samples as com-
pared to VLPs.
Negative staining followed by transmission electron
microscopy (TEM) revealed that the DENV VLPs are
fairly monodispersed, but heterogeneous in morphology
and size (Fig. 2). The VLPs appear as semi-smooth
spherical particles, with noticeable roughness at their
surface. The diameter of ~ 250 VLPs of each serotype
shows a size distribution between 25 and 40 nm, with
DENV3 and DENV4 VLPs being slightly bigger (~ 34–
35 nm) in size compared to DENV1 and DENV2 VLPs
(~ 29–30 nm).
DENV VLPs display similar epitopes than native virus
To compare antibody epitopes displayed by DENV VLPs
and infectious virions, we analyzed the binding of a large
panel of well-characterized human and mouse derived
mAbs (Table 1) to serially diluted VLPs and virions by
capture ELISA. Cross-reactive mAbs 4G2 and 1 M7
were used to capture purified virus and VLPs. The tested
mAbs vary from serotype specific (TS) or cross-reactive
(CR) mAbs that bind epitopes of different complexities
and the VLPs and purified fractions were derived from
the same batch as used in the CBB, WB and TEM ana-
lysis. Figure 3 depicts binding to a virus/VLP concentra-
tion of 1.32 ng/μl, which fell in the linear range of mAb
binding, which was determined by serial dilutions (data
not shown). Binding of the different mAbs to virus anti-
gen can be qualitatively compared to the binding of the
mAbs to purified VLPs. For DENV1, binding is observed
for the DENV1 TS mAb 1F4 for both virus and VLP
samples (Fig. 3a). With the exemption of C10, all CR
mAbs such as 1 M7, EDE1 (C8, C10), EDE2 (A11, B7),
1C19, 4G2 and 12C1.5 bind efficiently to DENV1 VLPs.
a
b
Fig. 2 TEM analysis of DENV1–4 VLPs. a Particle shape and distribution was analyzed by TEM using negative staining. b VLP size distribution was
determined by measuring the diameter of ~ 250 particles of each serotype
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Similar serotype specificity was found for DENV2–4
VLPs. TS mAb 2D22 and 3H5 show specific binding to
DENV2 VLPs (Fig. 3b), where binding is absent in the
other serotypes. For DENV3, specific binding was ob-
served by 5 J7 and 8A1 (Fig. 3c) and all CR mAbs bound
both virus and VLPs. CR binding was observed to a
lesser extent for DENV4 VLPs (Fig. 3d). Although the
TS mAbs 5H2, DV4 126, DV4 131 and DV4 141 bound
DENV4 virus and VLPs accordingly, binding of e.g. EDE
mAbs to DENV VLPs was marginal. Interestingly, only
minor binding of C10 was observed to any of the VLPs.
Due to the experimental setup, binding signals of the
same mAb to virus or VLP cannot be quantifiably com-
pared. However, it is possible to get a relative insight
a
b
c
d
Fig. 3 Epitope analysis of DENV1–4 VLPs. a-d DENV VLPs and virus particles were subjected to a large panel of human and mouse derived,
serotype specific (grey bars) or cross-reactive mAbs (black bars) that recognize epitopes of varying complexity (Table 1) by antigen capture ELISA.
Quaternary epitope recognizing (Q) mAbs and binding regions are indicated
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into the differences in epitope exposure and abundance
between virus and VLP. For this, we normalized the
binding of each mAb to a well-characterized TS, quater-
nary epitope mAb of each of the 4 serotypes. By compar-
ing the relative binding of each mAb between virus and
VLP, one can demonstrate that certain epitopes are bet-
ter represented on virus particles or VLPs. Future stud-
ies are needed for conclusive evidence, it does however
give an indication on the relative epitope exposure.
Binding of each mAb was normalized to 1F4 (DENV1)
, 2D22 (DENV2), 5 J7 (DENV3) and 5H2 (DENV4)
(Additional file 1). These are well characterized serotype
specific mAbs that bind to quaternary epitopes. Normal-
ized binding of each mAb to VLPs was subtracted from
the normalized binding to purified virus, resulting in
relative epitope binding (REB) (Fig. 4). Relative to 1F4
binding, 1 M7 and 12C1.5 epitopes are better displayed
on DENV1 VLPs than on DENV1 virus particles,
whereas the C10 and 1C19 epitopes were better dis-
played on DENV1 virions than on VLPs (Fig. 4a). For
DENV2, we observed enhanced binding of the EDE1
and EDE2 mAbs, relative to 2D22. Only 3H5 and
12C1.5 are significantly better recognized on DENV2
VLPs, compared to DENV2 virus (Fig. 4b). 12C1.5
binding was also found to be more proficient on
DENV3 VLPs compared to virus particles. 1 M7, EDE
mAbs and 1C19 binding was increased on DENV3
virus particles normalized to 5 J7 (Fig. 4c). Interest-
ingly, many of the DV4 TS and CR mAbs such as
4G2 and 12C1.5 bind DENV4 VLPs better than virus
particles, when normalized to 5H2.
DENV infected patient sera is efficiently depleted by
DENV VLPs
To characterize infection or vaccine induced immune re-
sponses, it is essential to determine if DENV serotype spe-
cific or cross-reactive antibodies are responsible for the
neutralizing activity in patient sera. These assays are trad-
itionally performed by coating purified infectious virus
particles to polystyrene beads, which are subsequently
used to capture and deplete different antibody populations
from serum samples. Using VLPs instead of infectious
virus would offer many practical advantages in these sero-
logical assays. We depleted DENV patient convalescent
sera (DT000) with DENV VLPs of each serotype individu-
ally. DT000 has been infected with multiple DENV sero-
types > 20 years ago and has been shown to efficiently
neutralize all 4 serotypes [21]. DENV VLPs and purified
virus were efficiently crosslinked to magnetic beads and
used to deplete DT000 of all DENV specific antibodies.
The ability of VLPs to deplete DENV sera was directly
compared to that of virus particles (Fig. 5). VLPs of all
DENV serotypes depleted DT000 sera equally well as virus
particles (Fig. 5a). In accordance with depleted IgG levels,
DT000 sera depleted with VLPs has completely lost its
neutralizing activity (Fig. 5b).
Discussion
The immunogenic properties of DENV VLPs have been
analyzed in animal models by several groups. However,
little is known about E-protein organization on the sur-
face of VLPs [10, 11]. VLP epitope display has not yet
been directly compared to that of virus particles and
Fig. 4 Relative epitope binding on DENV virus vs VLPs. To demonstrate that certain epitopes are better represented on virus particles or VLPs,
binding of each mAb within every DENV serotype was normalized to 1F4 (DENV1), 2D22 (DENV2), 5 J7 (DENV3) and 5H2 (DENV4). The normalized
binding of each mAb to VLPs was subtracted from the normalized binding to purified virus, resulting in relative epitope binding (REB). Quaternary
epitope recognizing (Q) mAbs and binding regions are indicated
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outside the use as vaccine antigens, VLP applicability as
serological tools has been underappreciated. The terms
subviral particle and VLP are often used to describe the
same particle format, but can be considered different. In
this study we refer to particles that do not contain a nu-
cleocapsid and are produced after the expression of
prM-E as VLPs. In our opinion, the term subviral par-
ticle is better used to describe the formation of smaller
spherical particles obtained as a side product of wildtype
infections.
DENV1–4 VLPs produced in mammalian cells effi-
ciently display epitopes that have mapped on virus parti-
cles. TS and CR monoclonal antibodies isolated from
different DENV patients with varying infection history
bound to the VLPs indicating that native epitopes are
present on the VLPs. In the low resolution cryo-EM
structural data available on flavivirus virus-like particles
or subviral particles, 30 E-dimers are assembled in a T =
1 icosahedral lattice, different from the 90 E-dimers
found on mature virus particles organized in a T = 3
symmetry [12]. Our analysis here demonstrates that
overall differences in arrangement of E-dimers on VLPs
versus virions and the absence or presence of a nucleo-
capsid do not alter the display of most quaternary epi-
topes targeted by human antibodies.
The DENV VLPs were found to have a similar size dis-
tribution as the TBEV subviral particles. With particle di-
ameters of ~ 29–34 nm, the VLPs are considerably smaller
in size than natural virus particles (~ 50 nm) [4, 12, 22].
The minor VLP size differences between serotypes could
be attributed to maturation dissimilarities, however, as the
highly concentrated VLPs are not perfect spheres and
have structural irregularities, the measurements of
diameters might be error prone. Future structural studies
are needed to confirm the observed differences in DENV
VLP diameter.
Human mAb 1F4 is DENV1 specific and although it
only binds the virus and not the E-monomer, its foot-
print has been mapped within one E-monomer and not
across neighboring E-proteins within the homodimer
[7]. Despite differences in size and prM content, 1F4
bound equally well to DENV1 VLPs and purified virus.
Similar results were found for 2D22 (DENV2), 5 J7
(DENV3) and 5H2 (DENV4). 2D22 is a potent neutraliz-
ing antibody and binds epitopes that span across the E-
protein dimer, blocking envelope reorganization neces-
sary for viral fusion [5]. DENV3 specific mAb 5 J7 has a
footprint that spans across neighboring E-dimers includ-
ing residues at the EDI/EDII hinge region [23]. Binding
of 5 J7 to DENV3 VLPs strongly indicates that E-dimers
interact and form poly-dimer structures similar to the
rafts found on virion surfaces. For long, 5H2 was the
only DENV4 specific highly neutralizing mAb of which
the binding footprint has been mapped. This chimpan-
zee derived mAb docks within EDI of E [24]. It does not
bind monomeric E-proteins, but efficiently binds both
DENV4 virus and VLPs. Recent studies have identified
new DENV4 TS mAbs that bind E-protein in ranging
complexity [8]. DV4 126 and DV4 131 are highly
neutralizing and their quaternary footprint was
mapped to the EDI/EDII hinge region. Just like 5 J7,
these mAbs do not bind monomeric E-proteins, but
recognize virus and VLPs.
We used 1F4, 2D22, 5 J7 and 5H2 to normalize the
binding of all the other mAbs to both virus and VLP,
allowing for a relative comparison between epitope
a
b
Fig. 5 DENV infected patient sera is efficiently depleted by DENV VLPs. Purified DENV particles or DENV VLPs were coated onto magnetic beads
and incubated with convalescent patient sera. BSA was used for the depletion handling control. a DENV specific IgG levels for all depletion
samples were determined by ELISA. b DENV specific neutralizing antibody titers were analyzed by a Vero-cell flow cytometry based neutralization
assay. Neutralizing titers are expressed as Neut50 values indicating the serum dilution where 50% of the virus is neutralized
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availability on virus vs VLPs. Relative to these mAbs we
see that the EDIII binding mAbs 12C1.5 and 3H5 bind
better to VLPs, indicating that the EDIII might be more
exposed on VLPs. The quaternary CR EDE epitopes are
relatively better presented on DENV2–3 virus particles.
In particular EDE1-C10 binding has a strong preference
for virus particles, due to the absence of binding to VLPs
of all serotypes. It remains unclear why C10 does not
bind VLPs, while the other EDE mAbs, that share a very
similar footprint, bind efficiently.
The maturity of virus particles and VLPs affects epi-
tope display as exemplified by the fusion loop binding
CR mAb 4G2. During virus replication, the pr peptide
associates with the fusion loop in E, shielding it from
premature low-pH induced fusion with host cell mem-
branes [25]. Our analysis indicates that the fusion loop is
efficiently exposed on DENV4 VLPs, which is in accord-
ance to the undetectable prM levels in DENV4 VLPs.
Differences in prM levels between DENV2–3 VLPs and
virus might have similar steric hindrance effects on the
EDE mAbs. However, this requires further structural
analysis. In general, epitopes present on the fusion loop
domain, EDIII and DI/DII/DIII spanning regions are all
represented on DENV VLP surfaces.
The footprints of many mAbs have been mapped on
dimers generated from soluble monomeric E proteins.
Soluble E monomers crystallize into dimers and do not
contain prM. Even though it is assumed that the crystal-
lized dimers are structurally similar to E-dimers found
on virus particles, they might differ when part of com-
plex multiprotein complexes on VLP envelopes. Future
studies should focus on DENV VLP protein structures
to answer these questions.
The VLPs and virus particles were captured by
mAbs 4G2 and 1 M7, suggesting a bias for fusion
loop exposed particles. However, using other captur-
ing mAbs, the bias would be skewed towards particles
displaying that specific epitope. Using other well-
characterized mAbs, we have shown that DENV VLPs
display an epitope landscape very similar to that
found on virus particles. Depletion studies using VLPs
as a depletion antigen translate this finding to poly-
clonal sera of DENV infected patients. Secondary in-
fected serum was efficiently depleted from all TS and
CR (non)-neutralizing antibodies. Serum depletions
are usually performed using infectious purified virus
antigen conjugated to microbeads. However the use
of VLPs has practical benefits over the use of purified
antigen. Issues of infectious virus production and
purification and virus leaching into the serum during
handling are not present when using VLPs. Addition-
ally, VLPs are more easily genetically adapted and are
therefore valuable tools in flavivirus pAb and mAb
mapping and serology.
Conclusions
Flavivirus VLP based vaccines are amongst the leading
candidates in ongoing vaccine studies. Understanding
the structure of VLPs is essential for interpreting the
antibody response in vaccinees. VLPs also have potential
value as diagnostic reagents. Besides, VLPs can be pro-
duced as a byproduct of natural infection. Therefore, the
structure of VLPs also becomes important from the
standpoint of virus assembly. By exploiting antibodies
and insights high resolution structure of dengue virions,
this study aids in further understanding the antigenic
landscape of DENV VLPs and presents a comparative
antigenic surface view of VLPs in respect to virus
particles.
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